<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525534</url>
  </required_header>
  <id_info>
    <org_study_id>261299</org_study_id>
    <nct_id>NCT04525534</nct_id>
  </id_info>
  <brief_title>Plasma Concentration of Biological Markers in Placenta Accreta Spectrum</brief_title>
  <official_title>Plasma Concentration of Biological Markers in Placenta Spectrum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this exploratory study is to determine how well maternal serum biomarkers and&#xD;
      placental micro-particles (MP) correlate with placenta accreta spectrum (PAS) at the time of&#xD;
      cesarean delivery in women with suspected PAS compared to women without PAS. Our aim is to&#xD;
      determine if women with PAS have a unique MP and protein signature at the time of delivery&#xD;
      compared with women without PAS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal blood samples will be taken at various points during the intrapartum period. A&#xD;
      healthy group of women admitted for delivery will act as a matched control and will have&#xD;
      their blood sampled at similar time points. The primary outcome variables will include the&#xD;
      total number of micro-particles, the number of micro-particles from each cell line (platelet,&#xD;
      placental, endothelial etc.), and protein markers The knowledge gained from this study has&#xD;
      the potential to develop a diagnostic test for PAS with the ability to improve management and&#xD;
      outcomes for mother and baby through earlier diagnosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the level of placental-derived MPs (Microparticles/mL)</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Determine quantitatively the level of placental-derived MPs which may be altered in 10 subjects with PAS and 10 phenotypically-matched controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify biomarkers (picogram/mL)</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Determine quantitatively the level of biomarkers which may be altered in 10 subjects with PAS and 10 phenotypically-matched controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Is there a correlation between maternal serum total placental MPs and biomarkers to the International Federation of Gynecology and Obstetrics (FIGO) classification for PAS at the time of cesarean delivery.</measure>
    <time_frame>Up to 6 hours</time_frame>
    <description>Examine the correlation between maternal serum total placental MPs and biomarkers to the FIGO classification</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Placenta Accreta</condition>
  <condition>Placenta Diseases</condition>
  <arm_group>
    <arm_group_label>Placenta accreta spectrum</arm_group_label>
    <description>Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenotypically-matched controlled group</arm_group_label>
    <description>Mother-infant dyads admitted for delivery without placenta accreta spectrum</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood for serum biomarkers and placental micro-particles.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mother-infant dyads with suspected or confirmed diagnosis of PAS and healthy mother-infant&#xD;
        dyads admitted for cesarean delivery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - to 45-years old, inclusive&#xD;
&#xD;
          -  Suspected or confirmed PAS or phenotypically matched controls&#xD;
&#xD;
          -  Delivery by cesarean section&#xD;
&#xD;
          -  Gestational age greater than 28 weeks&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intrauterine fetal demise,&#xD;
&#xD;
          -  Severe fetal anomalies (infant not expected to survive)&#xD;
&#xD;
          -  Emergent cesarean delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadir e Sharawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadir Sharawi, MD</last_name>
    <phone>5016866114</phone>
    <email>nelsharawi@uams.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadir Sharawi, MD</last_name>
      <phone>501-319-2622</phone>
      <email>nelsharawi@uams.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
    <mesh_term>Placenta Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

